Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
metastatic non small cell lung cancer epidemiology forecast

Metastatic Non-small Cell Lung Cancer Epidemiology Report

SALE

Metastatic Non-small Cell Lung Cancer Epidemiology Forecast– 2034

Published Date : 2025

Pages : 315

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

Metastatic Non-small Cell Lung Cancer Epidemiology

· As per DelveInsight’s analysis, the total incident cases of NSCLC in the 7MM were approximately 531,800 cases in 2023; these cases are estimated to increase by 2034.

· Among EU4 countries, Germany accounted for the highest number of NSCLC cases in 2023, whereas Spain accounted for the lowest cases in 2023.

· NSCLC is diagnosed at an advanced stage in nearly 50% of patients. Increased screening and detection have resulted in a concomitant rise in the incidence of Stage I NSCLC and a decline in Stage IV NSCLC.

· Various types of mutations are commonly observed in NSCLC. There is mounting evidence that substantial molecular and clinical heterogeneity exists within oncogenic driver-defined subgroups of NSCLC. The most frequent biomarkers are EGFR in Japan and KRAS in the US and Europe.

· EGFR exon 19 deletions and Exon 21 L858R substitution (sensitizing mutations) account for approximately 80% of EGFR mutations in NSCLC.

· The total incident cases of EGFR Non-small Cell Lung Cancer in the US was ~30,300 in 2023.

· The most frequent KRAS variant observed in NSCLC is G12C. In the United States, KRASG12C is present in ~37% of NSCLC cases.

· In 2023, the total incident cases of NTRK metastatic Non-small Cell Lung Cancer in the 7MM

was around 1,100.

DelveInsight's “Metastatic Non-small Cell Lung Cancer – Epidemiology – 2034” report delivers an in-depth understanding of metastatic non-small cell lung cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

· The United States

· EU4 (Germany, France, Italy, and Spain) and the United Kingdom

· Japan

Study Period: 2021-2034

Metastatic Non-small Cell Lung Cancer Disease Understanding

Metastatic Non-small Cell Lung Cancer Overview and Diagnosis

Non-small Cell Lung Cancer is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. Early diagnosis offers the best prognosis for Non-Small Cell Lung Cancer. However, Non-Small Cell Lung Cancer and other lung cancers can be difficult to diagnose because these cancers often have symptoms mistaken for common illnesses or the effects of long-term smoking. Because of this, 80% of people diagnosed with Non-Small Cell Lung Cancer have already progressed to advanced stages, making it more difficult to treat. If lung cancer is suspected, the physician will recommend imaging tests (CT, PET, or MRI scans) to identify abnormalities in and around the lungs. The physician may also examine a sample of mucus under the microscope.

If these initial tests identify cancer, a lung biopsy can be conducted. A bronchoscopy can also be recommended, allowing the physician to visualize and remove tissue. If lung cancer is confirmed, genetic testing can be done on the lung tissue to identify details about the cancer that can help inform metastatic non-small cell lung cancer treatment.

Further details related to country-based variations in diagnosis are provided in the report…

Metastatic Non-small Cell Lung Cancer Epidemiology

The Metastatic Non-small Cell Lung Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Non-small Cell Lung Cancer, total incident cases of Non-small Cell Lung Cancer by histology, total cases of Non-small Cell Lung Cancer by stages, total incident cases of Non-small Cell Lung Cancer by genetic mutation/biomarkers, total treated cases of Non-small Cell Lung Cancer by line of therapies in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034.

In the US, in 2023, there were approximately 202,500 new cases of lung cancer (~114,200 in men and ~88,300 in women). About 10–15% of all lung cancers are SCLC, and about 80–85% are Non-Small Cell Lung Cancer.
The three main histological subtypes of Non-Small Cell Lung Cancer are Adenocarcinoma, Squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the United States, approximately 57% of all lung cancers are adenocarcinomas. About 25–30% of all lung cancers are Squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up around 2% of all lung cancers.
Among the age-specific contribution, age ≥65 years are affected more by NSCLC than age <65 years. In 2023, there were 138,600 cases of NSCLC in age ≥65 years in the United States.
In the US, in 2023, there were approximately 110,000 metastatic cases of NSCLC (De novo advanced/metastatic patients and recurrent patients from early stages).
The two main subtypes of KRAS Non–Small Cell Lung Cancer are KRAS G12C, and KRAS non-G12C (G12V, G12D, G13D, G12R, and others). In the United States, ~22,300 cases comprised of KRAS G12C, and ~38,400 cases comprised of KRAS non-G12C in 2023.

Scope of the Report

The report covers a segment of executive summary, and a descriptive overview of metastatic non-small cell lung cancer, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of the metastatic non-small cell lung cancer epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
A detailed review of current challenges in establishing the diagnosis.

Metastatic Non-Small Cell Lung Cancer Report Insights

Patient Population
Patient population by stage and age
Country-wise Epidemiology Distribution

Metastatic Non-Small Cell Lung Cancer Report Key Strengths

Ten Years Forecast
The 7MM Coverage
Metastatic Non-small Cell Lung Cancer Epidemiology Segmentation

Metastatic Non-Small Cell Lung Cancer Report Assessment

Epidemiology Segmentation
Current Diagnostic Practices

FAQs

What are the disease risks and burdens of metastatic non-small cell lung cancer? What will be the growth opportunities across the 7MM concerning the patient population with metastatic non-small cell lung cancer?
What is the historical and forecasted non-small cell lung cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Which age group is the largest contributor in patients affected with metastatic non-small cell lung cancer?
Which biomarker has the highest patient share in metastatic non-small cell lung cancer?

Reasons to buy

Insights on patient disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Stay Updated with us for Recent Articles

Related Infographics of the Report

1: Key Insights

2: Report Introduction

3: Key Highlights

4: Executive Summary

5: Metastatic NSCLC Epidemiology Overview at a Glance

5.1 Patient Share (%) Distribution by Immune/Molecular Biomarker in 2021

5.2 Patient Share (%) Distribution by Immune/Molecular Biomarker in 2034

6 Epidemiology Methodology

7 Disease Background and Overview

7.1 Introduction

7.1.1 Cellular Classification of NSCLC

7.1.2 Signs and Symptoms of NSCLC

7.1.3 Risk Factors of Lung Cancer

7.1.4 Causes of NSCLC

7.1.5 Disease Biology: NSCLC

7.1.5.1 Genomic Alterations

7.1.5.2 Tumor Microenvironment

8 Diagnosis of NSCLC

8.1 Stages of NSCLC

8.2 Staging System

9 Epidemiology and Patient Population

9.1 Key Findings

9.2 Assumptions and Rationale: The 7MM

9.3 Total Incident Cases of NSCLC in the 7MM

9.4 United States Epidemiology

9.4.1: Total Incident Cases of NSCLC in the United States

9.4.2: Gender-specific Cases of NSCLC in the United States

9.4.3: Age-specific Cases of NSCLC in the United States

9.4.4: Total Incident Cases of NSCLC by Histology in the United States

9.4.5: Total Incident Cases of NSCLC by Stage in the United States

9.4.6: Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States

9.4.7: Line-wise Treated Cases of Metastatic NSCLC in the United States

9.5 EU4 and the UK Epidemiology

9.5.1: Total Incident Cases of NSCLC in EU4 and the UK

9.5.2: Gender-specific Cases of NSCLC in EU4 and the UK

9.5.3: Age-specific Cases of NSCLC in EU4 and the UK

9.5.4: Total Incident Cases of NSCLC by Histology in EU4 and the UK

9.5.5: Total Incident Cases of NSCLC by Stage in EU4 and the UK

9.5.6: Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK

9.5.7: Line-wise Treated Cases of Metastatic NSCLC in EU4 and the UK

9.6 Japan Epidemiology

9.6.1: Total Incident Cases of NSCLC in Japan

9.6.2: Gender-specific Cases of NSCLC in Japan

9.6.3: Age-specific Cases of NSCLC in Japan

9.6.4: Total Incident Cases of NSCLC by Histology in Japan

9.6.5: Total Incident Cases of NSCLC by Stage in Japan

9.6.6: Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan

9.6.7: Line-wise Treated Cases of Metastatic NSCLC in Japan

10 Appendix

10.1 Bibliography

10.2 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables:

Table 1: Summary of NSCLC Epidemiology (2021-2034)

Table 2: TNM Staging of NSCLC

Table 3: Total Incident Cases of NSCLC in the 7MM (2021-2034)

Table 4: Total Incident Cases of NSCLC in the United States (2021-2034)

Table 5: Gender-specific Cases of NSCLC in the United States (2021-2034)

Table 6: Age-specific Cases of NSCLC in the United States (2021-2034)

Table 7: Total Incident Cases of NSCLC by Histology in the United States (2021-2034)

Table 8: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2021-2034)

Table 9: Total Incident Cases of Advanced/Metastatic NSCLC in the United States (2021-2034)

Table 10: Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States (2021-2034)

Table 11: Line-wise Treated Cases of Metastatic NSCLC in the United States (2021-2034)

Table 12: Total Incident Cases of NSCLC in EU4 and the UK (2021-2034)

Table 13: Gender-specific Cases of NSCLC in EU4 and the UK (2021-2034)

Table 14: Age-specific Cases of NSCLC in EU4 and the UK (2021-2034)

Table 15: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2021-2034)

Table 16: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2021-2034)

Table 17: Total Incident Cases of Advanced/Metastatic NSCLC in the EU4 and the UK (2021-2034)

Table 18: Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK (2021-2034)

Table 19: Line-wise Treated Cases of Metastatic NSCLC in EU4 and the UK (2021-2034)

Table 20: Total Incident Cases of NSCLC in Japan (2021-2034)

Table 21: Gender-specific Cases of NSCLC in Japan (2021-2034)

Table 22: Age-specific Cases of NSCLC in Japan (2021-2034)

Table 23: Total Incident Cases of NSCLC by Histology in Japan (2021-2034)

Table 24: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2021-2034)

Table 25: Total Incident Cases of Advanced/Metastatic NSCLC in Japan (2021-2034)

Table 26: Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan (2021-2034)

Table 27: Line-wise Treated Cases of Metastatic NSCLC in Japan (2021-2034)

List of Figures:

Figure 1: Major Types of NSCLC

Figure 2: Signs and Symptoms of NSCLC

Figure 3: Risk Factors of NSCLC

Figure 4: Stage IIIB Lung Cancer

Figure 5: Stage IIIC Lung Cancer

Figure 6: Stage IVA Lung Cancer

Figure 7: Stage IVB Lung Cancer

Figure 8: Tumor Biomarker Testing Rate

Figure 9: Total Incident Cases of NSCLC in the 7MM (2021-2034)

Figure 10: Total Incident Cases of NSCLC in the United States (2021-2034)

Figure 11: Gender-specific Cases of NSCLC in the United States (2021-2034)

Figure 12: Age-specific Cases of NSCLC in the United States (2021-2034)

Figure 13: Total Incident Cases of NSCLC by Histology in the United States (2021-2034)

Figure 14: Total Incident Cases of NSCLC by Stage (at diagnosis) in the United States (2021-2034)

Figure 15: Total Cases of NSCLC by Genetic Mutations/Biomarkers in the United States (2021-2034)

Figure 16: Line-wise Treated Cases of Metastatic NSCLC in the United States (2021-2034)

Figure 17: Total Incident Cases of NSCLC in EU4 and the UK (2021-2034)

Figure 18: Gender-specific Cases of NSCLC in EU4 and the UK (2021-2034)

Figure 19: Age-specific Cases of NSCLC in EU4 and the UK (2021-2034)

Figure 20: Total Incident Cases of NSCLC by Histology in EU4 and the UK (2021-2034)

Figure 21: Total Incident Cases of NSCLC by Stage (at diagnosis) in EU4 and the UK (2021-2034)

Figure 22: Total Cases of NSCLC by Genetic Mutations/Biomarkers in EU4 and the UK (2021-2034)

Figure 23: Line-wise Treated Cases of Metastatic NSCLC in EU4 and the UK (2021-2034)

Figure 24: Total Incident Cases of NSCLC in Japan (2021-2034)

Figure 25: Gender-specific Cases of NSCLC in Japan (2021-2034)

Figure 26: Age-specific Cases of NSCLC in Japan (2021-2034)

Figure 27: Total Incident Cases of NSCLC by Histology in Japan (2021-2034)

Figure 28: Total Incident Cases of NSCLC by Stage (at diagnosis) in Japan (2021-2034)

Figure 29: Total Cases of NSCLC by Genetic Mutations/Biomarkers in Japan (2021-2034)

Figure 30: Line-wise Treated Cases of Metastatic NSCLC in Japan (2021-2034)

Tags:

License Type

Offer